Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
AstraZeneca and Takeda Pharmaceutical are joining to develop MEDI1341, an antibody from AstraZeneca intended to treat Parkinson’s disease. MEDI1341 binds to and inhibits α-synuclein, a protein that accumulates in the nerve cells of people with Parkinson’s. Takeda will pay AstraZeneca up to $400 million. AstraZeneca will lead Phase I clinical trials, which are set to start later this year.
This article has been sent to the following recipient: